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PURPOSE. To identify mutations in FAM161A underlying autosomal recessive retinitis
pigmentosa (arRP) in the Dutch and Belgian populations and to investigate whether common
FAM161A-associated phenotypic features could be identified.
METHODS. Homozygosity mapping, amplification-refractory mutation system (ARMS) analysis,
and Sanger sequencing were performed to identify mutations in FAM161A. Microsatellite and
SNP markers were genotyped for haplotype analysis. Patients with biallelic mutations
underwent detailed ophthalmologic examinations, including measuring best-corrected visual
acuity, extensive fundus photography with reflectance and autofluorescence imaging, and
optical coherence tomography.
RESULTS. Homozygosity mapping in 230 Dutch individuals with suspected arRP yielded five
individuals with a homozygous region harboring FAM161A. Sanger sequencing revealed a
homozygous nonsense mutation (c.1309A>T; p.[Arg437*]) in one individual. Subsequent
ARMS analysis and Sanger sequencing in Dutch and Belgian arRP patients resulted in the
identification of seven additional individuals carrying the p.(Arg437*) mutation, either
homozygously or compound heterozygously with another mutation. Haplotype analysis
identified a shared haplotype block of 409 kb surrounding the p.(Arg437*) mutation in all
patients, suggesting a founder effect. Although the age of onset was variable among patients,
all eight developed pronounced outer retinal loss with severe visual field defects and a bull’s
eye–like maculopathy, followed by loss of central vision within 2 decades after the initial
diagnosis in five subjects.
CONCLUSIONS. A founder mutation in FAM161A p.(Arg437*) underlies approximately 2% of
arRP cases in the Dutch and Belgian populations. The age of onset of the retinal dystrophy
appears variable, but progression can be steep, with almost complete loss of central vision
later in life.
Keywords: FAM161A, retinitis pigmentosa, founder mutation, bull’s eye–like maculopathy
Retinitis pigmentosa (RP; MIM[268000]) is a set of hereditaryretinal dystrophies affecting more than 1 million people
worldwide. It is a progressive disease that typically presents
with degeneration of the rod photoreceptors, followed by loss
of cone photoreceptor function. Most patients experience
night blindness as the initial symptom. Subsequently, a gradual
constriction of the peripheral visual fields occurs, followed by
loss of central vision. The clinical presentation of RP is highly
variable and is matched by an impressive genetic heterogeneity:
currently, mutations in 55 genes have been implicated in the
pathogenesis of autosomal recessive RP (arRP).1,2 Genes that
are mutated in RP encode proteins with diverse functions in
multiple cellular processes, including the phototransduction
cascade, the visual cycle, cytoskeletal dynamics, regulation of
gene transcription, and ciliary function.2
In 2010, two back-to-back studies revealed null-mutations in
FAM161A as a cause of arRP in the Israeli and German
population, respectively.3,4 FAM161A encodes a 716-aa protein
that localizes to the connecting cilium, the basal body region,
and the adjacent centriole in photoreceptor cells.5,6 The
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connecting cilium is a key structure in mediating the high-
throughput transport of essential proteins and lipids from the
inner segment (IS) to the outer segment (OS). The photore-
ceptor OS is in fact considered a specialized and modified
cilium that is not self-sustaining and relies on the IS for the
synthesis of the essential proteins and lipids.7 FAM161A is a
microtubule-associated ciliary protein presumably involved in
maintaining microtubule stability. The interaction with other
ciliary and centrosomal proteins known to be implicated in
retinal dystrophies, like SDCCAG8, CEP290, lebercilin, and
POC1B, points to a possible role for FAM161A in transport
processes between the IS and OS.5,6,8 In addition to its ciliary
function, a recent study presenting the FAM161A interactome
also suggests a role for FAM161A in more general cellular
processes, in the Golgi apparatus, centrosome, and/or the
microtubule network.9
In this study, we aimed to explore the contribution of
FAM161A mutations to the genetic spectrum of arRP in the
Dutch and Belgian populations. A previously described
nonsense mutation p.(Arg437*)3,10–12 was identified in eight
individuals, five times in a homozygous state and three times in
compound heterozygous state with another protein-truncating
mutation. Detailed clinical examinations revealed some com-
mon phenotypic features related to FAM161A-associated arRP.
METHODS
Subjects
This study was approved by the medical ethics committees of
the participating centers, and adhered to the tenets of the
Declaration of Helsinki. Before this study, patients and their
relatives consented to participate in this study, to retrieve the
medical records, and to analyze their DNA.
Genetic Evaluation
To identify conspicuous homozygous regions potentially
harboring the genetic defects underlying arRP in the Dutch
population, we previously performed genome-wide homozy-
gosity mapping in 230 affected individuals from 186 unrelated,
mainly nonconsanguineous families using the Affymetrix
GeneChip Genome-Wide Human SNP Array 5.0 platform.
Homozygous regions were identified using Partek genomic
suite software (Partek, St. Louis, MO, USA), as described
previously.13 In patients with homozygous regions encompass-
ing FAM161A (NM_001201543.1), all exons and intron-exon
boundaries of this gene were analyzed with Sanger sequencing
as reported previously.4 Following the identification of the
c.1309A>T; p.(Arg437*) mutation, the presence of this variant
was assessed in 100 Belgian and 184 Dutch unrelated
individuals affected with suspected autosomal recessive or
isolated RP using amplification-refractory mutation system
(ARMS) analysis. For this, three different primers were
designed: a wild-type (wt) forward primer (F_wt), a mutated
forward primer containing the c.1309A>T mutation at the 30
end (F_mut) and a wt reverse primer (R_wt). This mutation
was confirmed by Sanger sequencing in all mutation-positive
patients. All heterozygous carriers were screened for a second
mutation by amplifying all coding regions of FAM161A,
followed by Sanger sequencing (BigDye Terminator v3.1 Cycle
Sequencing Kit on an ABI 3730XL genetic Analyzer; Applied
Biosystems, Foster City, CA, USA). A single heterozygous
patient, for whom no second mutated allele was found, was
screened for mutations in two FAM161A-associated CRX-
bound regions (CBRs).3,14 Furthermore, quantitative PCR
(qPCR) analysis on genomic DNA was performed to determine
the presence of any coding copy number alterations, as
previously described.15 qBasePlus software (Biogazalle, Zwij-
naarde, Belgium) was used for data-analysis16 and two
reference genes were used for normalization of the relative
quantities. Two positive controls with known copy number
were used as a reference to calculate the copy numbers.15
Conventional PCR primers were designed using Primer3Plus,17
qPCR primers using PrimerXL (http://www.primerxl.org/, in
the public domain). All primer sequences can be found in
Supplementary Table S1. Patient numbering is used throughout
the text only for patients having a homozygous (P1-P5) or
compound heterozygous FAM161A mutation (P6-P8). The
patient with only one heterozygous mutation is referred to as
Phet.
Haplotype Analysis
In total, 19 markers were genotyped (see Supplementary Table
S2), 18 of which were single nucleotide polymorphisms
(SNPs), and one flanking microsatellite. Five of the 18 SNPs
were included because of their presence in the haplotypes of
the German patients described by Langmann et al.3 Thirteen
additional tagging SNPs were selected using the QuickSNP
software.18 All primer sequences can be found in Supplemen-
tary Table S1.
Clinical Evaluation
We collected the available clinical data from the medical files of
all eight patients with two FAM161A mutations, and retro-
spective data on visual acuity were converted into logMAR
scores. Some patients were reevaluated after the identification
of the causative FAM161A mutations. Ophthalmic examination
included measurement of best-corrected visual acuity (BCVA)
(Early Treatment Diabetic Retinopathy Study charts; Precision
Vision, Inc., La Salle, IL, USA), biomicroscopy, ophthalmosco-
py, and fundus photography. Additional tests were Goldmann
kinetic perimetry and ERG according to the standards of the
International Society for Clinical Electrophysiology of Vision
(ISCEV).19 Spectral-domain optical coherence tomography (SD-
OCT) and blue-light (488 nm) autofluorescence imaging (BAF;
Heidelberg Spectralis HRAþOCT; Heidelberg Engineering,
Heidelberg, Germany) was carried out as described previous-
ly.20 As FAM161A-related arRP is a ciliopathy and ciliopathies
can be quite diverse and involve other organ systems, we used
a questionnaire to identify extraocular features, such as
nephropathy, polydactyly, intellectual disability, and obesity.
Phet is not included in the clinical overview given in the Table,
due to the lack of clinical information.
RESULTS
Identification of FAM161A Mutations
Following genome-wide homozygosity mapping in a large
cohort of Dutch RP patients,13 five patients with homozygous
regions of at least 2 Mb encompassing FAM161A were analyzed
for mutations in this gene. In one individual (P1), a
homozygous nonsense mutation was identified, c.1309A>T;
p.(Arg437*) (Fig. 1A). This mutation had previously been
identified in three German families segregating arRP.3 To
further explore the prevalence of this mutation in the Dutch
and Belgian populations, ARMS analysis was performed for this
mutation (Fig. 1A). Of 284 patients, 2 additional patients
carried the p.(Arg437*) mutation in a homozygous state (P2
and P3), whereas 4 individuals were heterozygous carriers of
this mutation. Screening of the coding region revealed a
second heterozygous mutation in three of them, that is, P6
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carried a 1-bp deletion leading to a frameshift and the
incorporation of a premature stop codon (c.1501del, p.[Cy-
s501Valfs*4]), P7 carried a second nonsense mutation
(c.1567C>T, p.[Arg523*]), and P8 carried a mutation abolish-
ing the 50 splice site of the first intron (c.183þ1G>T). No
second exonic mutation was detected in the fourth heterozy-
gous carrier Phet. Copy number variations of the coding region
of FAM161A as a potential second mutation were excluded by
genomic qPCR analysis. Since the expression of FAM161A is
known to be strictly regulated by the retinal transcription
factor CRX, reflected by the association of the gene with two
evolutionarily conserved upstream and intronic CBRs respec-
tively (Supplementary Fig. S1), we hypothesized that disrup-
tion of the binding sequence for CRX could alter the regulation
of this gene.14 Hence, both CBRs were sequenced for this
individual but no sequence variation was identified. Interest-
ingly, Phet had two nieces with RP, whose DNA was not present
in the initial cohort. Sanger sequencing subsequently revealed
the p.(Arg437*) mutation to be present in homozygous state in
these two sisters (P4 and P5). Of note, both sisters also carry a
heterozygous mutation in RPE65 (c.11þ5G>A) that is recur-
rently present in the village where they live. In total, eight
individuals were identified with biallelic mutations in
FAM161A, with the p.(Arg437*) representing at least one of
the two alleles in all cases. All FAM161A mutations identified in
this study are depicted in Figure 1B.
The p.(Arg437*) Mutation in FAM161A Is a Founder
Mutation
Given the high prevalence of the p.(Arg437*) mutation in the
Dutch and Belgian cohorts, on top of the fact that this mutation
had also been described in the German population,3 we
hypothesized that this allele may represent a founder mutation.
To assess this, haplotype analysis was performed in all patients
carrying this mutation by genotyping the 5 SNPs reported by
Langmann et al.3 and extended by 13 additional SNPs. The
haplotype was compared with the previously reported
haplotype of the German patients. All individuals homozygous
for the p.(Arg437*) mutation (P1 to P5), were also homozygous
FIGURE 1. FAM161A mutations identified in this study. (A) Identification of FAM161A founder mutation. Results of the ARMS reaction and
subsequent Sanger sequencing analysis in patients homozygous for the c.1309A>T mutation, P (hom), heterozygous patients, P (het) and controls
with two wild-type (wt) alleles, C (wt). The ARMS analysis consisted of two PCR reactions for every patient, one with a forward primer matching the
wt allele (WT lane), the other one with a primer matching the mutated allele (MUT lane). P (hom) will only have amplification in the MUT lane, P
(het) in both lanes and C (wt) only in the WT lane. Every mutation detected with the ARMS reaction was confirmed by Sanger sequencing. (B)
Overview of FAM161A mutations identified in this study. The p.(Arg437*) founder mutation (red) is located in the third and largest exon of
FAM161A. Presence of this mutation has been demonstrated in a total of nine Dutch and Belgian patients, of which five were homozygous for this
mutation. In three heterozygous patients, a second mutation has been identified (black): c.183þ1G>T, disrupting the 50 splice site of the first intron;
p.(Cys501Valfs*4), a frameshift mutation leading to the incorporation of a premature stop codon; p.(Arg523*), a second nonsense mutation further
downstream in the third exon. In one patient (Phet) no second mutation was identified.
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for a number of investigated SNPs surrounding the mutation,
allowing construction of the haplotype carrying the nonsense
mutation. The three individuals who carried compound
heterozygous mutations (P6 to P8) also carried one of these
haplotypes, together with a different haplotype harboring the
second mutation. In addition, the disease haplotype identified
in this study corresponded to the haplotype of the German
patients who were homozygous for the p.(Arg437*) mutation
(Fig. 2). The 17 SNPs (rs7609513–rs7574631) that together
define the shared haplotype block are spread out over a region
of 409 kb, delimited by recombination events at flanking SNP
rs1406002 and flanking microsatellite D2S337, pointing to a
maximal length of 910 kb for the common haplotype and
further emphasizing that the p.(Arg437*) mutation represents a
founder allele. Not taking into account the initial patient P1
included in the homozygosity study, Phet and her two nieces P4
and P5, we identified the founder mutation either in
homozygous or compound heterozygous state in 5 out of
284 patients, corresponding to a prevalence of approximately
2% in the Dutch and Belgian populations.
Clinical Evaluation
Eight affected individuals from seven families were included in
the study and an overview of the mutations and the clinical
data is presented in the Table and Figure 3. The p.(Arg437*)
mutation was found in a homozygous state in five patients of
four families, albeit that there was no reported parental
consanguinity but for P8, whereas P4 and P5 originate from
a genetic isolate.
The initial symptom was night blindness in all eight affected
individuals, but the age at which it was noted varied from 6 to
25 years. In patient P2, the diagnosis was established during a
routine ophthalmic checkup at the age of 11 years; it took
another 4 years before this patient became aware of night
blindness. Subjects P7 and P8 experienced night blindness
from the age of 7 and 6, but were only diagnosed with RP at the
age of 32 and 25, respectively, indicating that the night
blindness did not have an impact on their daily life and was not
a reason to consult an ophthalmologist at an earlier age.
The nyctalopia was followed by progressive concentric
constriction of the peripheral visual fields in all patients, and
deterioration of central vision.
Of six patients, follow-up data on BCVA were available and
are displayed in Figure 4. These data show a loss of central
vision after the age of 25 and legal blindness (visual acuity [VA]
< 20/400, logMAR 1.3) in the sixth decade in P2 and P3. The
other four individuals retained good central vision (‡20/40,
logMAR 0.3) even within the sixth decade (P4 and P5) but with
small visual fields. No extensive follow-up data were available
on P7 and P8, but BCVAs in the better eye were light
perception (LP) with localization and decimal BCVA of 0.05
(logMAR 1.3) at ages 43 and 63 years, respectively, with self-
reported rapid deterioration of central vision at ages 30 and 36,
respectively.
All patients displayed a mild to moderate myopia; anisome-
tropia was the cause of amblyopia in patient P1. Posterior
subcapsular cataracts were present in all eight patients. These
typical cataracts developed from the third decade; patient P8
underwent cataract extractions at the ages of 57 left eye (LE)
and 58 right eye (RE).
Ophthalmoscopy revealed the classic symptoms of RP
consisting of waxy pallor of the optic discs and in advanced
cases pale-white discs, attenuated retinal vessels, and atrophy
of the RPE and choriocapillaris in the midperiphery with
intraretinal spicular pigmentation in all eight, combined with
FIGURE 2. Haplotype analysis of FAM161A locus in Dutch, Belgian, and German patients. Eighteen SNPs and one microsatellite marker spread over
a region of 910 kb (chr2: 61,669,931 [D2S337]–62,579,956 [rs1406002] [hg19]) were used to perform haplotype analysis in the eight individuals
carrying the putative p.(Arg437*) founder mutation. An identical (orange) haplotype block of 409 kb (chr2: 61,825,142 [rs7574631]–62,234,345
[rs7609513] [hg19]) linked to disease could be identified in each of the patients. As expected, the five homozygous patients (P1–P5) described in
this study and the three homozygous German patients described by Langmann et al.3 carried two copies of this disease haplotype block, whereas
the three heterozygous patients had only one copy. Remarkably, P8 and Phet appear to share the same haplotype combination, while the splice site
mutation identified in P8 was absent in Phet.
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deep intraretinal nummular pigmentations in two (P7 and P8).
In four subjects (P1, P4, P5, and P6), a bull’s eye–like
maculopathy consisting of mild RPE alterations surrounding
the fovea was documented at some stage of the disease. In
patient P6, this lesion became apparent at age 24. In the three
older patients (P2, P3, and P8), a narrow ring of recognizable
retinal tissue that surrounds the completely atrophic macular
center (Fig. 3) was observed, respectively at age 62, 65, and 67.
The retinal tissue peripheral to this ring is also severely
atrophic with disseminated, irregular pigmentary deposits. In
patients P2 and P3, central ring-like depigmentation or bull’s
eye–like macular lesions were seen at ages 44 and 53,
respectively. Patient P7 displayed a relatively preserved fovea
but without function.
Electroretinogram responses could not be elicited in any of
the patients, not even at the early stages.
The BAF images on recent examination revealed a hyper-
autofluorescent ring around the fovea (Fig. 3) in patients P1,
P4, P5, and P6. In patients P2 and P8, hyperautofluorescence
in accordance with the doughnut-shaped preservation of the
RPE was seen. In patients P1, P4, P5, and P6 IS and OS
junctions were intact on OCT at the macular region, whereas
they were absent in the other three patients tested.
Although one of the patients (P1) was treated for
hypertension and diabetes, we did not detect any extraocular
features that were suggestive for syndromic RP.
DISCUSSION
Genetic evaluation of FAM161A in a Dutch and Belgian cohort
of genetically unsolved arRP patients, revealed eight individuals
with biallelic FAM161A mutations. All individuals carried at
least one c.1309A>T, p.(Arg437*) nonsense mutation; five
were homozygous, whereas three were compound heterozy-
gous in conjunction with a second protein-truncating allele. In
addition, in one affected heterozygous individual related to two
affected homozygous individuals, no second FAM161A muta-
tion could be found despite copy number screening and
evaluation of retina-specific CBRs. However, mutations in
FIGURE 3. Clinical overview. (A–C) Images of P6, taken at the age of 25 years. (A) Fundus photograph of the RE showing minimal optic disc pallor,
attenuated vessels, wrinkling of the inner limiting membrane, mild RPE alterations around the fovea, and atrophy in the midperiphery. (B) Fundus
autofluorescence of the LE showing a hyperautofluorescent ring around the fovea and hypoautofluorescent patches in the midperiphery. (C)
Optical coherence tomography of the LE showing intact IS/OS junctions at the macula. (D–F) Images of P2 at age 62. (D) Fundus photograph of the
LE at the age of 32 years showing mild pallor of the optic disc, attenuated vessels, distinct RPE atrophy around the fovea, atrophy in the
midperiphery with bone-spicule pigmentations. (E) Infrared image of the LE at the age of 65 years showing a preserved rim of RPE around the
macula with complete atrophy of the fovea. (F) Optical coherence tomography of the LE at the age of 65 years showing severely atrophic retina with
a relatively preserved retina with a RPE/choroid band in the area corresponding with the ring that surrounds the macula. (G–I) Images of P7, taken
at the age of 43 years. (G) Composite fundus photograph of RE showing waxy optic discs with temporal pallor, severely attenuated retinal vessels,
RPE atrophy more pronounced in confluent round flecks around vascular arcades and inferiorly, and mixed nummular and bone-spicule
pigmentations in the periphery. (H) Fundus autofluorescence of the RE showing marked hypoautofluorescence of area around optic disc and
vascular arcades, with nummular patches of hypoautofluorescence in midperiphery. (I) Optical coherence tomography of the RE showing
preserved RPE and photoreceptors immediately inferior to atrophic fovea.
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noncoding regions of FAM161A such as deep intronic
mutations, or involvement of mutations in a different retinal
dystrophy gene cannot be excluded. Haplotype analysis
revealed that the p.(Arg437*) mutation represents a founder
allele present in the Dutch, Belgian, and German population.
Following homozygosity mapping, five patients from our
cohort showed a significant homozygous region encompassing
FAM161A, but only one of these carried a homozygous
FAM161A mutation p.(Arg437*). Yet, this mutation was
detected homozygously in four other patients from our cohort.
As it appeared, these patients were either not analyzed by
homozygosity mapping (P4 and P5) or the homozygous region
surrounding the p.(Arg437*) mutation was below the threshold
of 250 consecutive homozygous SNPs that was used to identify
significant homozygous regions.13 The relatively small size of
the common haplotype block identified in all mutation
carriers, including the previously described German patients,3
supports the hypothesis that this mutation is an ancestral allele
that has spread over northwest Europe, explaining the
relatively high prevalence of this mutation in our arRP cohorts.
However, the disease haplotype described by Rose et al.12 in
British patients with the p.(Arg437*) mutation is different,
indicating that this mutation has arisen de novo in at least two
different European populations.
Despite a number of recent studies, the exact function of
FAM161A is not completely understood. In gene trapped
Fam161a mice, it was shown that Fam161a is located in the
cilia of rod and cone photoreceptors and that this protein is
vital for the integrity of the connecting cilium. The structural
abnormalities in these Fam161aGT/GT mice implicate a crucial
role for this protein in the structural composition, mainte-
nance, and function of the connecting cilium; the latter was
also demonstrated by the misrouting of the cargo proteins
opsin and rds/peripherin.21 In our study, as well as in
previously published work, the vast majority of FAM161A
alleles are protein-truncating mutations that are predicted to
completely abolish the function of the FAM161A protein,
whereas only two missense mutations have been reported so
far.10,22 Hence, impaired transport of proteins essential for
phototransduction in the OS of photoreceptor cells is the most
likely molecular mechanism underlying FAM161A-associated
arRP.
From a clinical point-of-view, the limited number of
previous studies dealing with FAM161A mutations has shown
a wide range of disease severity,3,4,12,23,24 although only two
reports focus on the phenotype.12,24 As in other studies, the
age of onset of FAM161A-associated RP in our patient cohort
was variable, ranging from the first to the third decade of life.
Most patients with FAM161A-associated RP display lens
opacities and a mild to moderate myopia. This applies to the
Dutch/Belgian patients in this study, but was also mentioned
by others.4,23 However, it is not a finding limited to RP caused
by mutations in FAM161A.
Despite clinical variability in disease severity, age of onset,
and progression, a specific finding in the current study was the
very distinct ‘‘ring’’ or ‘‘doughnut’’ of relatively preserved
retinal tissue surrounding the macula. This phenomenon was
present in three older patients in their seventh decade. The
fact that two of these patients had documented bull’s eye–like
lesions in their fourth and fifth decades, as well as the presence
of bull’s eye–like maculopathy in two younger patients (P1 and
P6) seems to suggest that these phenotypes may be sequential.
Although the clinical description is often limited, bull’s eye–
like patterns can be observed in the fundus photographs of
some FAM161A-RP patients in other studies.4,12,24 One of the
patients in the report by Bandah-Rozenfeld et al.4 shows a
FIGURE 4. Evolution of VA in patients with FAM161A mutations. Graph showing the evolution of BCVAs expressed in logMAR (y-axis) over time
(age, x-axis) for six patients (P1–P6) carrying mutations in the FAM161A gene. For P7 and P8, no extensive follow-up data were available, only
showing the VA at two and one time points, respectively. Snellen VA was transformed into logMAR for visualization purposes. A logMAR value of 1.9
was assigned to counting fingers (CF), 2.3 to hand movements (HM), and 2.7 to LP. When the VA differed in both eyes, the eye with the best VA at
onset was used. When the VA at onset was identical, the recordings of the RE were taken.
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fundus autofluorescence image that may even be indicative of a
ring of preserved retinal tissue around the macular center.
It would be interesting to investigate whether the presence
of a bull’s eye–like maculopathy precedes atrophy of the
posterior pole, and would thereby act as a negative prognostic
factor for VA in FAM161A-related RP. Or, as suggested by Rose
et al.,12 that there might be two different phenotypes as
observed by fundus autofluorescence pattern.
Progression of the FAM161A RP phenotype results in legal
blindness in our older patients. This bleak prognosis for VA
later in life was also observed by Langmann et al.,3 but in a
recent report by Duncan et al.,24 VA appeared remarkably
well preserved, even in older patients. The notion in the latter
study that foveal cones are preserved until the late stages of
disease progression was therefore not corroborated by our
study, adding to the evidence that this phenotype is indeed
highly variable. FAM161A-related arRP is a ciliopathy and the
phenotypes of this group of disorders can be quite diverse
and known to involve other organ systems. We used a
questionnaire to identify extraocular features, but except for
one patient known with diabetes and hypertension, none of
the patients show such associations. Obviously, this does not
allow us to entirely and reliably exclude the presence of
syndromal abnormalities that can only be brought to light
with additional investigations, for instance blood tests or
renal ultrasonography in case of renal developmental
abnormalities.
In conclusion, we have identified a founder mutation in
FAM161A underlying visual impairment in approximately 2%
of Dutch and Belgian arRP patients. The phenotype of the
Dutch/Belgian FAM161A-related retinal dystrophy is character-
ized by a severe chorioretinal atrophy that involves the
posterior pole in the later stages, resulting in a very low BCVA
that is often limited to LP. A bull’s eye pattern was present in
most of the patients in the early to midphase of the disease.
This maculopathy may well progress to complete central
chorioretinal atrophy with the exception of a thin ‘‘ring’’ or
‘‘doughnut’’ shape of relatively preserved retinal tissue
surrounding the posterior pole.
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